TickerFacts.

Black Diamond Therapeutics, Inc. (BDTX): Revenue

Annual figures by period end, from SEC filings.

$70.00M
Year ended 2025-12-31
$0
Trailing 12 months to 2026-06-30
2024-12-31: $02025-12-31: $70.00M$70.00M
2024-12-31 Revenue (USD) 2025-12-31
Period endedRevenueChange YoYSource filing
2025-12-31$70.00Mn/a2026-03-16, From 2025-01-01
2024-12-31$0n/a2026-03-16, From 2024-01-01

Revenue at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedRevenueChange YoY
Black Diamond Therapeutics, Inc. (BDTX)2025-12-31$70.00Mn/a
Vir Biotechnology, Inc. (VIR)2025-12-31$68.56M-7.6%
Compugen Ltd (CGEN)2025-12-31$72.76M+161.1%
Recursion Pharmaceuticals, Inc. (RXRX)2025-12-31$74.68M+26.9%
Autolus Therapeutics plc (AUTL)2025-12-31$75.39M+644.9%
MeiraGTx Holdings plc (MGTX)2025-12-31$81.39M+144.6%
Champions Oncology, Inc. (CSBR)2026-04-30$59.42M+4.4%
4D Molecular Therapeutics, Inc. (FDMT)2025-12-31$85.21Mn/m
Invivyd, Inc. (IVVD)2025-12-31$53.43M+110.5%

Compare BDTX, VIR, CGEN, RXRX side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗